Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress
08. August 2024 08:30 ET
|
Adlai Nortye Ltd.
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a global clinical-stage biotechnology...
Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors
08. August 2024 08:00 ET
|
Adlai Nortye Ltd.
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a global clinical-stage biotechnology...
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
23. Mai 2024 21:03 ET
|
Adlai Nortye Ltd.
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology...
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
22. Mai 2024 08:00 ET
|
Adlai Nortye Ltd.
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company...
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
29. März 2024 06:00 ET
|
Adlai Nortye Ltd.
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage...
Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC
17. November 2023 07:30 ET
|
Adlai Nortye Ltd.
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology...
Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award
23. Oktober 2023 08:12 ET
|
Adlai Nortye Ltd.
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a global clinical-stage biotechnology...
Adlai Nortye Ltd. Announces Closing of Initial Public Offering
03. Oktober 2023 12:05 ET
|
Adlai Nortye Ltd.
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology...
Adlai Nortye Ltd. Announces Pricing of Initial Public Offering
29. September 2023 02:46 ET
|
Adlai Nortye Ltd.
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage...